Resource Summary Report

Generated by RRID on Aug 2, 2026

Oncomine Research Platform

RRID:SCR_007834
Type: Tool

Proper Citation

Oncomine Research Platform (RRID:SCR_007834)

Resource Information

URL: http://www.oncomine.org

Proper Citation: Oncomine Research Platform (RRID:SCR_007834)

Description: Oncomine Research Platform is a partially-commercial suite of products for online cancer gene expression analysis dedicated to the academic and non-profit research community. Oncomine combines a rapidly growing compendium of 20,000+ cancer transcriptome profiles with a sophisticated analysis engine and a powerful web application for data-mining and visualization. Oncomine facilitates rapid and reliable biomarker and therapeutic target discovery, validation and prioritization. Oncomine was developed by physicians, scientists, and software engineers at the University of Michigan and is now fully supported for the academic and non-profit research community by Compendia Bioscience.

Synonyms: OncoMine

Resource Type: data analysis service, service resource, production service resource, analysis service resource

Keywords: FASEB list

Resource Name: Oncomine Research Platform

Resource ID: SCR_007834

Alternate IDs: nif-0000-03218, OMICS_00775, SCR_010949

Record Creation Time: 20220129T080244+0000

Record Last Update: 20260801T190341+0000

Ratings and Alerts

No rating or validation information has been found for Oncomine Research Platform.

No alerts have been found for Oncomine Research Platform.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 3661 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Karapouliou C, et al. (2025) HMMR has oncoprotein-like properties in neuroblastoma cells and high HMMR expression has independent prognostic potential in neuroblastomas. Scientific reports, 15(1), 40434.

Wang W, et al. (2025) Unveiling the impact of C15orf48 on non-small cell lung cancer through NF-kappa B signaling. Biomolecules & biomedicine, 25(5), 1162.

Wei J, et al. (2025) PlexinD1 is a driver and a therapeutic target in advanced prostate cancer. EMBO molecular medicine, 17(2), 336.

Yang G, et al. (2025) NDRG1 enhances the sensitivity to Cetuximab by promoting Stat1 ubiquitylation in colorectal cancer. Journal of advanced research, 72, 555.

Uno K, et al. (2025) Implication of KLHL Gene Family Member KLHL5 in Colorectal Cancer Progression and Prognosis. Cancer science, 116(9), 2580.

Nie H, et al. (2025) Upregulation of RIG-I is Critical for Responsiveness to IFN-?? Plus Anti-PD-1 in Colorectal Cancer. Cancer medicine, 14(6), e70802.

Shan H, et al. (2025) USP24 promotes hepatocellular carcinoma progression by deubiquitinating and stabilizing YAP1. Cancer cell international, 25(1), 164.

Dong S, et al. (2025) The prognostic value of mitogen-activated protein kinase kinase in liver hepatocellular carcinoma by bioinformatics. Medicine, 104(26), e42933.

Ding Z, et al. (2025) The expression and prognostic value of CCL19 in breast cancer. Discover oncology, 16(1), 830.

Levine SR, et al. (2025) Report of the 2023 Mary Tyler Moore Vision Initiative Workshop. Translational vision science & technology, 14(7), 11.

Qiu X, et al. (2025) TAGLN2-mediated Actin Cytoskeleton Stabilization Promotes Proliferation and Metastasis of Ovarian Carcinoma. Applied immunohistochemistry & molecular morphology : AIMM, 33(4), 242.

Xianhong Z, et al. (2025) SIRT5-mediated desuccinylation of MTHFD2 enhances chemoresistance in breast cancer cells by reducing therapy-induced senescence. Communications biology, 8(1), 1485.

Zhang J, et al. (2025) Multi-omics analysis reveals the panoramic picture of TOP2A in pan-cancer. Scientific reports, 15(1), 6046.

Yuan R, et al. (2025) TRIB3 is a biomarker of poor prognosis in laryngeal squamous cell carcinoma and may affect tumor development through PI3K / AKT / mTOR pathway. Clinics (Sao Paulo, Brazil), 80, 100576.

Zhang X, et al. (2025) The transcription factor TSHZ3 promotes tumor immunosuppression and inhibits metastasis in lung adenocarcinoma. Frontiers in immunology, 16, 1519815.

Xu Z, et al. (2025) The expression of CD109 in B-cell acute lymphoblastic leukemia and its potential as a promising marker for minimal residual disease (MRD) detection. Clinical and experimental medicine, 25(1), 292.

Mulder CV, et al. (2025) A comparative study of four cell-free DNA assays for detecting circulating tumor DNA in early breast cancer. Breast cancer research : BCR, 27(1), 120.

Hossain MS, et al. (2025) Exploring the oncogenic role and prognostic value of CKS1B in human lung adenocarcinoma and squamous cell carcinoma. Frontiers in genetics, 16, 1449466.

He L, et al. (2025) Increased SLC7A3 Expression Inhibits Tumor Cell Proliferation and Predicts a Favorable Prognosis in Breast Cancer. Recent patents on anti-cancer drug discovery, 20(1), 55.

Khan F, et al. (2025) Identification and Validation of Biomarkers to Predict Early Diagnosis of Inflammatory Bowel Disease and Its Progression to Colorectal Cancer. Biochemical genetics, 63(4), 3717.